William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andrew Brackmann has given his Buy rating due to a combination of factors including Sera Prognostics’ progress in Medicaid pilot programs and their strategic steps towards increasing the adoption of their PreTRM test. The company is actively working on establishing a foundation for broader market penetration by focusing on coverage and reimbursement strategies, clinician awareness campaigns, and building a commercial team.
Brackmann also highlights the significance of the upcoming PRIME study publication, which is expected to provide additional data supporting future reimbursement and uptake. Although an increase in revenue and test volumes may take some time, the groundwork being laid by Sera Prognostics is seen as a positive indicator for future growth and market opportunity, justifying the Buy rating.
According to TipRanks, Brackmann is a 5-star analyst with an average return of 32.3% and a 68.09% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Hologic, and QuidelOrtho.